Azithromycin Patent Expiration
Azithromycin was first introduced by Pfizer Chemicals Div Pfizer Inc
Azithromycin Patents
Given below is the list of patents protecting Azithromycin, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Zmax | US6984403 | Azithromycin dosage forms with reduced side effects |
Feb 14, 2024
(Expired) | Pf Prism Cv |
| Zmax | US7887844 | Multiparticulate crystalline drug compositions having controlled release profiles |
Feb 14, 2024
(Expired) | Pf Prism Cv |
| Azasite | US6239113 | Topical treatment or prevention of ocular infections |
Mar 31, 2019
(Expired) | Thea Pharma |
| Azasite | US6569443 | Topical treatment or prevention of ocular infections |
Mar 31, 2019
(Expired) | Thea Pharma |
| Azasite | US7056893 | Topical treatment for prevention of ocular infections |
Mar 31, 2019
(Expired) | Thea Pharma |
| Azasite | US6861411 | Method of treating eye infections with azithromycin |
Nov 25, 2018
(Expired) | Thea Pharma |
| Zithromax | US6268489 | Azithromycin dihydrate |
Jul 31, 2018
(Expired) | Pfizer |
| Zithromax | US6268489 | Azithromycin dihydrate |
Jul 31, 2018
(Expired) | Pfizer |
| Zithromax | US6268489 | Azithromycin dihydrate |
Jul 31, 2018
(Expired) | Pfizer |
| Zmax | US6268489 | Azithromycin dihydrate |
Jul 31, 2018
(Expired) | Pf Prism Cv |
| Azasite | US6159458 | Sustained release ophthalmic compositions containing water soluble medicaments |
Nov 04, 2017
(Expired) | Thea Pharma |
| Zmax | US6068859 | Controlled-release dosage forms of Azithromycin |
May 30, 2017
(Expired) | Pf Prism Cv |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Azithromycin's patents.
Latest Legal Activities on Azithromycin's Patents
Given below is the list recent legal activities going on the following patents of Azithromycin.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 13 Jul, 2022 | US7887844 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 16 Jul, 2018 | US7887844 |
| Patent Issue Date Used in PTA Calculation Critical
| 15 Feb, 2011 | US7887844 |
| Recordation of Patent Grant Mailed Critical
| 15 Feb, 2011 | US7887844 |
| Email Notification Critical
| 27 Jan, 2011 | US7887844 |
| Issue Notification Mailed Critical
| 26 Jan, 2011 | US7887844 |
| Dispatch to FDC | 10 Jan, 2011 | US7887844 |
| Application Is Considered Ready for Issue Critical
| 07 Jan, 2011 | US7887844 |
| Issue Fee Payment Verified Critical
| 05 Jan, 2011 | US7887844 |
| Issue Fee Payment Received Critical
| 05 Jan, 2011 | US7887844 |
Azithromycin's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Azithromycin:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
